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Abstract
Background: The clinical effectiveness of intensive lifestyle interventions in preventing or delaying diabetes in
people at high risk has been established from randomised trials of structured, intensive interventions conducted in
several countries over the past two decades. The challenge is to translate them into routine clinical settings. The
objective of this review is to determine whether lifestyle interventions delivered to high-risk adult patients in
routine clinical care settings are feasible and effective in achieving reductions in risk factors for diabetes.
Methods: Data sources: MEDLINE (PubMed), EMBASE, CINAHL, The Cochrane Library, Google Scholar, and grey
literature were searched for English-language articles published from January 1990 to August 2009. The reference
lists of all articles collected were checked to ensure that no relevant suitable studies were missed. Study selection:
We included RCTs, before/after evaluations, cohort studies with or without a control group and interrupted time
series analyses of lifestyle interventions with the stated aim of diabetes risk reduction or diabetes prevention,
conducted in routine clinical settings and delivered by healthcare providers such as family physicians, practice
nurses, allied health personnel, or other healthcare staff associated with a health service. Outcomes of interest were
weight loss, reduction in waist circumference, improvement of impaired fasting glucose or oral glucose tolerance
test (OGTT) results, improvements in fat and fibre intakes, increased level of engagement in physical activity and
reduction in diabetes incidence.
Results: Twelve from 41 potentially relevant studies were included in the review. Four studies were suitable for
meta-analysis. A significant positive effect of the interventions on weight was reported by all study types. The
meta-analysis showed that lifestyle interventions achieved weight and waist circumference reductions after one
year. However, no clear effects on biochemical or clinical parameters were observed, possibly due to short follow-
up periods or lack of power of the studies meta-analysed. Changes in dietary parameters or physical activity were
generally not reported. Most studies assessing feasibility were supportive of implementation of lifestyle
interventions in routine clinical care.
Conclusion: Lifestyle interventions for patients at high risk of diabetes, delivered by a variety of healthcare
providers in routine clinical settings, are feasible but appear to be of limited clinical benefit one year after
intervention. Despite convincing evidence from structured intensive trials, this systematic review showed that
translation into routine practice has less effect on diabetes risk reduction.
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The clinical effectiveness of intensive lifestyle interven-
tions in preventing or delaying development of dia-
betes in people at high risk has been established from
randomised controlled trials of structured, intensive
interventions conducted over the past two decades in
the USA [1,2], China [3], Finland [4,5], and India [6].
These interventions, promoting healthy eating and
moderate physical activity, have shown that sustained
weight loss of 3.5 kg or more can be achieved with
lifestyle interventions, and that onset rates of diabetes
can be reduced by as much as 58% in the first few
years. A protective effect of the lifestyle intervention of
about 43% has also been shown 20 years following the
initial intervention in a Chinese study [7]; and a 34%
reduction in diabetes incidence was shown to persist
10 years following an intervention in the USA [8].
There is also evidence, from a large cohort study, that
even without a formal intervention, diabetes risk was
lowered in people whose lifestyle change was consis-
tent with at least three of the goals of the Finnish Dia-
betes Prevention program [9]. The study’s authors
estimated that a further 20% reduction in the incidence
of diabetes after 4.6 years of follow-up would occur if a
further goal were met.
Calls for broader implementation of lifestyle interven-
tions for diabetes prevention in clinical settings are not
uncommon in the literature [10-17], although there has
been recognition that translation or replication of ran-
domised controlled trials is not straightforward, and
long-term sustainability is uncertain [18,19]. Application
of lifestyle recommendations and demonstrated replica-
tion of clinical trial approaches in routine clinical prac-
tice often are hindered by lack of resources or
reimbursement [20], lack of practitioners’ time or skill
[21,22], practical difficulties with recruitment, measure-
ment error, and poor patient retention due to the com-
plexities of the transition between awareness, motivation
and action [18,23,24]. Little systematic information
exists on the feasibility or effectiveness of replications of
these interventions (or less intensive and more generali-
sable settings for lifestyle intervention), and on achieve-
ment of expected associated benefits as part of routine
clinical practice.
To our knowledge, no compilations of trials or reviews
of replication studies as part of preventive care in rou-
tine clinical practice appear to have been reported.
Accordingly, this review presents a summary of out-
comes from the routine clinical context and examines
the feasibility of transferring the diabetes prevention
research to real-world settings. In short, the review
assesses the extent that outcomes from clinical trials of
lifestyle interventions into physical activity and nutrition
to lower diabetes risk have been replicated in routine
clinical practice.
Methods
Search strategy
The search was confined to English language articles
published between January 1990 and August 2009.
Three authors (MC-M, LR, AB) separately interrogated
different data sources using the same search terms (see
appendix). This was supplemented with hand searches
of the reference sections of other systematic reviews
[2,18,19,25-40]. Only studies which investigated at least
one of our research questions above, and which were
consistent with our inclusion criteria below, were con-
sidered in this review (Figure 1).
Study selection
The review focused on translational research studies
where interventions were based on any of the large
reference diabetes prevention RCTs mentioned above.
These could be: replication studies in the form of RCTs,
before/after evaluations, cohort studies with or without
a control group, or interrupted time series analyses,
where participants have been exposed to a lifestyle inter-
vention of at least 3 months duration and followed up
for at least 3 months. Routine clinical practice was
defined as a health service setting providing patient care
such as primary health clinics, hospital outpatient clinics
or specialist medical centres.
Intervention types
Interventions were classified as single (either nutrition
or physical activity programs with or without medica-
tion), or combined nutrition and/or physical activity
programs (structured or unstructured) whether or not
they included medication. Structured intervention com-
ponents were defined as those in which participants
received a standard set of sessions with instructions on
specific dietary and/or physical activity requirements
and goals. In unstructured interventions participants
were given generic advice on healthy living without spe-
cific goals other than improving diet or physical activity
in relation to baseline. The comparison group might be
‘no intervention group’ or an ‘alternative intervention’
(single or combined). Prevention programs delivering
diabetes education materials only were excluded. Like-
wise, medication-only studies were excluded. Only pro-
grams conducted in routine health services, delivered
on-site or in associated facilities, with outcomes mea-
sured in healthcare settings by general medical practi-
tioners, specialist physicians, practice nurses, dietitians,
physiotherapists, allied health professionals, community
health staff, or research staff attached to the health
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1990-2009.
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either had to be replications or modification of all or
some components of the US Diabetes Prevention Pro-
gram [DPP] [1] or Finnish Diabetes Prevention Study
[DPS] [5] or any other reference trial, or had to include
the reduction of diabetes risk or diabetes incidence
explicitly as a goal or objective.
Target group
Participants were adult men or women with any degree
of impaired glucose regulation (impaired fasting glucose
or impaired glucose tolerance) or with normal glycaemia
b u ta tr i s ko fd i a b e t e sa sd e t e r m i n e db yr i s kf a c t o r s
such as obesity or family history. They may have been
recruited from the primary or other healthcare patient
clientele or from the general population but had to
receive the intervention through routine healthcare ser-
vices. Participants’ risk of diabetes may have been deter-
mined by a diabetes risk score, either measured or from
self-report, and may have had accompanying blood glu-
cose tests to either identify impaired glucose regulation
or exclude diabetes before receiving the intervention.
Studies including patients with diagnosed diabetes were
included in this review only if they were a replication of
the reference trials and whose outcomes were reported
separately from participants without diabetes.
Outcomes of interest
Studies were included if they reported at least one of the
following main outcome measures of interest:
￿ Improvement in objectively measured risk factors
such as weight loss or waist circumference
reduction.
￿ Metabolic outcomes indicative of diabetes risk
reduction (improvement of fasting glucose levels,
improved 2-hour post-prandial plasma glucose, or
reduction of HbA1c)
￿ Self-reported or objectively measured behavioural
outcomes such as increased physical activity (min-
utes per day or METS per hour), increased fibre
consumption (grams per day or gm per KJ), or
reduction of fat intake (% of total energy intake).
The secondary outcome examined was:
￿ Prevention of diabetes (incidence %, or delay in
onset or reduction in incidence over a given follow-
up time).
Bias assessment
To assess the potential for bias, and given the heteroge-
neity of studies included in this review, a generalisability
and bias assessment tool covering elements of various
checklists and resources from the literature was specifi-
cally designed. Items examined included participant
recruitment source, selection criteria, treatment alloca-
tion, blindness of outcome assessment, simultaneous
collection of data for intervention and control groups,
measurement error, subgroup analysis and discussion of
study limitations (tool available from the authors on
request). Reference tools used for this design were
STROBE, COCHRANE Collaboration, CLEAR NPT,
EQUATOR, PRISMA, TREND and MOOSE [41-46].
One of the authors (MC-M) conducted the bias and
quality assessment of all studies and three other authors
(LR, SM & PTE) independently conducted the second
bias and quality assessment of some of the studies. Two
of the authors (MC-M & SM) independently extracted
results and assessed the appropriateness of statistical
analyses and conclusions.
Assessment of study quality
Study quality was assessed and graded on the following
criteria: (1) evidence of assessment of risk for diabetes
at enrolment; (2) explicit eligibility and exclusion cri-
teria; (3) reported participation rate of at least 50% of
eligible people; (4) follow-up assessment rates of ≥ 65%
of program participants by study conclusion or follow-
up; (5) evidence of measurable or explicit outcome
assessment; (6) appropriate statistical methods, including
adequate control for confounders (in non-RCTs); (7)
explicit intervention components; (8) conclusions sup-
ported by findings. A numeric score giving equal weight
to each of the above criteria was used to determine
quality. The maximum possible score was thus 8, indi-
cating highest quality.
Statistical analysis
The denominator for the effect sizes was the number of
subjects in whom the outcome had been assessed. Study
results were categorised as positive (statistically signifi-
cant difference observed), negative (no difference or sta-
tistically significant negative effect), or inconclusive
(showed no difference but lacked sufficient power to
detect a difference). Given the heterogeneity of designs,
length of follow-up and outcome measurements of the
available studies, pooling of selected results for a meta-
analysis was feasible only for four RCTs reporting
12-month follow-up results [47-50]. The remaining
eight studies were critically reviewed but not meta-ana-
lysed. Changes in means, and tests of heterogeneity
between trials were calculated using random effects
models. When not reported in individual studies, stan-
dard deviations of mean differences in outcome mea-
sures were calculated from supplied study participant
numbers and standard errors or from 95% confidence
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and-after differences in mean values. Meta-analysis was
conducted using NCSS software version 7.1.1.9 [51] on
the four main outcomes of interest: changes in weight,
fasting plasma glucose, waist circumference and 2-hour
OGTT.
Sensitivity analysis by study quality was not deemed
necessary as all four studies finally selected for meta-
analysis had a quality score of 7 or 8 out of the possible
8 maximum score. Our search did not identify unpub-
lished replication studies of diabetes prevention in rou-
tine clinical practice. Accordingly, we expected findings
not to be significantly affected by publication bias.
Results
Our searches identified 41 potentially eligible diabetes
prevention studies of lifestyle interventions in clinical
practice that included various combinations of diet and/
or exercise for diabetes risk reduction or diabetes pre-
vention. Of these, 18 studies were excluded because:
their replications of lifestyle interventions were con-
ducted in non-routine clinical settings (e.g. in commu-
nity settings such as homes, public centres, churches, or
workplaces) [52-59], or in a research setting [47,60-65];
or they did not include at least one of the outcomes of
interest [66,67]. A further 5 were excluded because they
were trials underway and/or had not published results
to date [16,68-70]; or they replicated a reference trial for
people who already had diabetes [71]. A further 6 stu-
dies were excluded because: the study compared results
retrospectively with reference trials without conducting
an intervention [9]; the intervention was confined to a
diabetes education component only [72,73]; the inter-
vention was telephone-based only and had not repli-
cated components of the reference trials [74]; or they
were either duplicates, companion or interim reports, of
studies already selected [75-77].
Differences in presentation of results (e.g. monthly
weight change without SD [78], or BMI change instead
of weight change [79], or FPG ranges instead of group
means [79]) precluded inclusion of two studies in the
meta-analysis. One study, with the largest sample size
[80], could not be meta-analysed to estimate the effects
of a lifestyle intervention, as both the medication and
placebo arms received the lifestyle intervention, i.e. the
study measured the effects of medication as an adjunct
to lifestyle intervention.
The final set of 12 studies covered in this review
included 7 randomised controlled trials (including one
cluster RCT), 3 before-after designs without a control
group and two before-after designs with a control group
(Table 1). The studies were conducted in 8 OECD coun-
tries, and had sample sizes ranging from 58 to 3,304
(median 311), with participant ages ranging from 20 to
79 years; six of the studies targeted middle-aged people
only. All interventions combined physical activity and
dietary advice, two studies also included medication as
part of the intervention [50,80], and all were delivered
in routine clinical settings, such as specialist services or
hospital outpatient clinics (5), general practitioner con-
sulting rooms (5) or community health services (2). Staff
delivering the intervention were usually nurses or allied
health staff (8/12). The target groups were people at
high risk, defined either by the presence of impaired
glucose tolerance, severe obesity, or metabolic syndrome
or some of its components. Eight of these studies also
included normoglycaemic patients and two replication
studies included both subjects with and without diabetes
and pre-diabetes.
Types of lifestyle interventions reported
All studies included a combined lifestyle intervention
but two eligible studies included a medication arm in
addition to lifestyle. Seven studies attempted replication
of the reference trial approaches from either the U.S
DPP [1] or the Finnish DPS [81] with adaptation to rou-
tine clinical practice, mostly to cater for limitations in
practitioner’s time and health service budgets
[14,48,49,78,82-84]. Modifications included: shorter
duration of program (2/7); delivery of group sessions
instead of individual face-to-face counselling (4/7);
reduced number and frequency of individual or group
counselling sessions to which participants were exposed
(5/7); and mixed group and individual program
approaches (1/7).
Modifications of interventions during the maintenance
phase included intermittent support sessions, more eco-
nomical versions of the resources given to participants,
and multidisciplinary teams, either available on site or
hired as an additional service. For interventions deliv-
ered in a group-based modality, the maximum number
of sessions per program was 16, as per the reference
trial [1] (median of 6 sessions), but over a shorter period
of time. Among the 5 studies reporting delivery of indi-
vidual counselling sessions, the median number of indi-
vidual counselling sessions was 13.5.
All dietary interventions were structured and half the
physical activity interventions were unstructured (Table
2). While some interventions were delivered with a core
intensive phase and an intermittent approach for the
maintenance phase, the median duration of intervention
was 32 weeks; follow-up periods also varied from 4 to
60 months with a median follow-up duration of
12 months. Delivery of the modified versions of the
reference trial interventions was mostly by nurses, psy-
chologists or allied health staff such as health promotion
counsellors, dietitians or exercise physiologists alone (8/
12) who provided the training, demonstration,
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mainly involved in assessing participant eligibility, refer-
ral and outcome measurement (7/12). Two studies did
not report the professional background of people deli-
vering the intervention or assessing the participants
[49,80].
Type of outcomes reported
Reported measured outcomes of interest were weight
(12/12), fasting plasma glucose (9/12) waist
circumference (7/12), and 2-hour OGTT (3/12) (Table
3). Six studies had follow-up periods enabling the exam-
ination of diabetes incidence or incidence reduction,
with the remainder confined to reporting risk improve-
ment via behavioural modification or improvement in
metabolic or anthropometric parameters. Self-reported
dietary and physical activity outcomes of interest amen-
able to statistical comparison were not often reported
and were confined to mean reduction in fat intake as a
percentage of total energy (3/12), and changes in fibre
Table 1 Classification of eligible studies by design, target population, outcomes and quality score (1990-2009)
Author,
year,
reference #
Study
Design
Total
sample
size
Target
age
group
Country &
Setting of
recruitment
Inclusion
criteria:
Normal or
abnormal GT
Loss to follow-
up rate %
Outcome assessment:
Measured OR
self-reported
Study
Quality
score
1
*Barclay,
2008 [87]
RCT 37 50-85 UK: Single
general
practice
IGT or IFG 19% Measured weight, WC, FPG, lipids, self-
reported exercise, 4-day food diary
7
Greaves,
2008 [86]
RCT 141 18+ UK: 2 GP
surgeries
NGT or IGT 18% Measured weight, WC and self-reported
physical activity
7
*Bo, 2007
[48]
RCT 375 45-64 Italy: Family
physician
GPs
Metabolic
Syndrome
11% Self-reported FFQ & exercise; Measured
FPG, insulin, weight, WC, lipids, CRP
8
*Kosaka,
2005 [49]
RCT 458 Adult
males
30+
Japan:
Hospital
outpatient
Clinic
IGT 15.9% Measured FPG, OGTT, HbA1c, measured
weight, lipids
7
Torgerson,
2004 [80]
RCT 3,304 30-60 Sweden:
Medical
centres
NGT & IGT 57% overall; 48%
on medication &
66% on placebo
Measured weight, WC,
FPG, lipids, serum insulin, fibrinogen
7
*Dyson,
1997 [50]
RCT 227 40-60 UK, France: 5
Hospitals
IFG 11% FPG, OGTT, HbA1c, lipids, measured
weight, max O2 uptake, self-reported 3-
day food record & physical activity log
7
Whittemore,
2009 [78]
CLU 58 21+ USA: Primary
care
practices
NGT & IGT 12% Self-reported exercise and nutrition
Measured weight, WC, insulin resistance,
lipids
7
McTigue,
2009 [84]
BAC 166 20-79 USA: Primary
care
practices
Obese, NGT or
diabetic
7% Measured weight 5
Eriksson,
1991 [79]
BAC 181 47-49 Sweden:
Borderline
diabetes
clinic
NGT & IGT 22.8% Self-reported exercise, max O2 uptake,
FPG, OGTT, lipids, measured weight,
skinfold, mortality
7
Pagoto,
2008 [14]
B-A 118 Middle
age
USA:
Academic
medical
center
Metabolic
syndrome, NGT
or diabetic
17% Measured weight, BP, 3
Laatikainen,
2007 [83]
B-A 311 40-75 Australia:
General
practices
NGT & IGT 23.8% Self-reported FFQ, SF-36, K10; Measured
FPG, 2 hr PG, WC, weight, lipids
7
Absetz, 2005
& 2009
[77,82]
B-A 352 50-65 Finland:
Primary
health care
centres
NGT & IGT 9.4% Self-reported 3-day food diary, physical
activity,
Measured weight, WC, FPG, lipids
7
BA = before-after; BAC = Before-after with a control group; BP = Blood pressure; CLU = Cluster-randomised trial; FFQ = Food frequency questionnaire; FPG =
Fasting plasma glucose; IGT = Impaired glucose tolerance; NGT = Normal glucose tolerance; PA = Physical activity; OGTT = Oral glucose tolerance test; RCT =
Randomised controlled trial; WC = Waist circumference.
*Study used for meta-analyses.
1 Higher quality score = higher study quality.
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Page 6 of 17Table 2 Description of studies by lifestyle components and modality of each intervention
Physical activity
program*
Dietary
modif-ication*
Face-to-face
Counselling
Phone
couns-elling
Outcome assessment Duration
(months)
Control
Intervention
Program
delivered
by
Outcomes
assessed
by
Author,
year
[reference]
Structured Unstructured No.
Individual
sessions
No.
Group
sessions
No. Objective Self-report Inter-vention Follow-up
Barclay,
2008 [87]
Y Y - 6 - Y Y 1 6 Usual
management
from GP or nurse
Nutritional
scientist,
psychologist,
aerobics instructor
Nutritionist,
research
assistant
Greaves,
2008 [86]
Y Y 11 2 Y Y 6 6 Usual care +
information only
Health promotion
counsellor
Researcher
Bo,
2007 [48]
Y Y 1 4 - Y Y 12 12 Usual care +
general verbal
information
GPs,
endocrinolog-ists,
nutritionists
Physician
Kosaka,
2005 [49]
Y Y 1 16 - Y Y 12 48 Verbal lifestyle
advice every 6
months
NR NR
Torgerson,
2004 [80]
Y Y 54 - - Y Y 48 48 Same lifestyle
advice minus
medication
Dieticians Doctors &
other PHC
staff
Dyson,
1997 [50]
Y Y 5 - - Y 12 12 Once only, written
basic lifestyle
advice
Dietician, fitness
instructor,
physician
NR
Whittemore,
2009 [78]
Y Y 6 - 5 Y Y 6 6 20-30 minutes
with nurse & 45
minutes with
nutritionist
Nurses Nurses
McTigue,
2009 [84]
Y Y 12 12 12 No intervention Nurses Physicians
Eriksson,
1991 [79]
Y Y 7 - - Y - 12 60 No specific
diabetes
prevention
intervention or no
intervention
Dietician, Nurse,
Physiotherapist
Doctor
Pagoto,
2008 [14]
Y Y 16 Y 4 4 No control group Dieticians,
psychologists,
exercise
physiologists
Physicians
Laatikainen,
2007 [83]
Y Y 6 Y Y 8 12 No control group Dieticians, Nurses,
Physiotherapist
Other PHC
Absetz,
2005,
2009 [82]
Y Y 6 Y 8 12 No control group Nurse, dietician,
Physiotherapist
Doctor,
Nurse
Y = Yes, reported NR = not reported GPs = general practitioners.
* Structured = Participants received standard set of sessions with instructions on specific dietary and/or physical activity requirements and goals;
Unstructured = participants were given generic instructions on improved lifestyle or had flexibility to apply them and no specific goal was set apart from improved diet or physical activity in relation to baseline.
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7Table 3 Results of measured outcomes and direction of effect reported at the end of the study: 1 year follow-up or
less, and 3-years or more (1990-2009)
Author,
year,
reference #
follow-up
time
Reduction in
diabetes
incidence
(%, OR, RR)
Incidence of
diabetes
Improvement of FPG or
2 h PG in mmol/L
% participants
achieving ≥ 5%
weight loss
Mean weight loss
Kg
Mean reduction
in WC (cm)
Results at one year or earlier
McTigue,
2009 [84]
1 year
NR NR NR 27% of
intervention vs.
6% of controls
achieved 7%
weight loss
-5.2 Kg intervention vs.
+0.2 Kg control
NR
Bo, 2007 [48]
1 year
Adjusted
OR = 0.23
(0.06-0.85)
1.8% in intervention
vs. 7.2% in controls
-0.26 mmol/L FPG
intervention vs. +0.07
controls
OR for IFG = 0.22 (0.13-
0.39)
-0.75 Kg in intervention
vs. +1.63 Kg in controls
-2.55 cm in
intervention vs.
+1.96 cm in
controls
Laatikainen,
2007 [83]
1 year
23% based on
weight loss;
40% based on
WC reduction
2.2% of IGT or IFG
participants
-0.14 mmol/L NR -2.5 Kg -4.2 cm
Kosaka, 2005
[49]
1 year
NR NR NR NR -2.5 Kg in intervention
vs.-0.39 Kg in control
NR
Absetz, 2005
[82]
1 year
NR 6% of those meeting
4-5 goals vs. 3% of
those meeting 3 or
fewer goals
+0.1 mmol/L ± 0.6 12% achieved 5%
weight loss
-0.8 Kg ± 4.5 Kg -1.6 cm ± 4.8 cm
Torgerson,
2004 [80]
1 year
NR NR NR 72.8% in
medication +
lifestyle vs. 45.1%
in placebo +
lifestyle
-10.6 Kg in medication
+lifestyle vs.
-6.2 Kg in placebo+
lifestyle
-9.6 cm in
medication
+lifestyle vs.
-7.0 cm in
placebo+ lifestyle
Dyson, 1997
[50]
1 year
NR NR -0.1 mol/L in intervention
vs.-0.2 mmol/L in control
NR -0.4 Kg in intervention
vs. -0.2 Kg in control
NR
Whittemore,
2009 [78]
6 months
NR N/A Reported no difference
between groups, but no
data shown
25% interv vs.
11% control
-0.5 cm
intervention vs.
-0.1 cm control
Greaves,
2008 [86]
6 months
NR N/A NR 23.6% interv
vs.7.2% control
Mean difference 1.3 Kg Mean difference
-1.6 cm
Barclay, 2008
[87]
6 months
NR N/A -0.02 mmol/L FPG
intervention vs. +0.25
mmol/L control at 6
months
-2.73 Kg intervention vs.
-0.3 Kg control
-6.01 cm
intervention vs.
-1.18 cm control
Pagoto, 2008
[14]
4 months
NR N/A NR 30% achieved 7%
weight loss
-5.5 Kg in whole
sample and -6.5 Kg in
participants without
comorbidities at 4
months
NR
(Laatikainen)
Kilkkinen,
2007 [75]
3 months
NR N/A No change NR -2.4 Kg -3.2 cm
Results at 6, 4 or 3 years
Eriksson,
1991 [79]
6 years
RR = 0.37 (0.20-
0.68)
10% prevalence in
intervention vs. 28.6%
prevalence in controls
52.2% normalized 2 hr
OGTT in intervention vs.
35.7% normalized in IGT
non-intervention controls
NR -3.3 Kg vs. +0.2 Kg NR
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Page 8 of 17intake (3/12). These are summarised in Table 4. Due to the heterogeneity of units used for measuring and
Table 4 Direction and magnitude of self-reported outcomes at end of program of any duration (1990-2009)
Author, year
and
reference #
Improvement in frequency of physical
activity/week
Reduction of fat intake Mean reduction
in energy %
Increased fibre intake in g/day
% achieved goal Mean change %
achieved
goal
Mean reduction %
achieved
goal
Mean increase
Whittemore,
2009 [78]
+17% in interv vs.
+1% in controls at 6
months
NR NR NR NR NR
Bo, 2007 [48] +4.73 MET-hr intervention
vs. in -0.26 MET-hr in
controls at 1 yr
-2.64% in intervention vs. -0.02%
in controls at 1 yr
+1.7 g/day
intervention vs. +0.17
g/d in controls
at 1 yr
Barclay, 2008
[87]
NR NR NR NR NR NR
Greaves, 2008
[86]
37.5% interv vs.
27.5% control
NR NR Reported successful reduction of
total fat and saturated fat but no
data shown
NR NR
Kosaka, 2005
[49]
NR NR NR NR NR NR
Torgerson,
2004 [80]
NR NR NR NR NR NR
Dyson, 1997
[50]
+0.17 L/min VO2max in
interv vs. -0.03 L/min in
controls at 1 yr
-3.5% in intervention vs.
-1.4% in control at 1 yr
+0.9 g/day
intervention vs. -0.7 g/
day in control at 1 yr
Eriksson,
1991 [79]
NR increase of 17% in IGT
and 9% Oxigen uptake at
1y r
NR NR NR NR
McTigue,
2009 [84]
NR NR NR NR NR NR
Pagoto, 2008
[14]
NR NR NR NR NR NR
Laatikainen
2007 [83]
NR NR NR NR NR NR
Absetz, 2005
[82]
66% NR 48% NR 52%
NR = not reported.
Table 3 Results of measured outcomes and direction of effect reported at the end of the study: 1 year follow-up or
less, and 3-years or more (1990-2009) (Continued)
Kosaka, 2005
[49]
4 years
67.4%
reduction in
intervention
group
3% intervention vs.
9.3% in control
53.8% intervention vs.
33.9% in control
NR -2.2 Kg in intervention
vs.
-0.39 Kg in control
NR
Torgerson,
2004 [80]
4 years
Total
intervention
group 37.3%;
IGT patients
45%
6.2% in medication +
lifestyle vs. 9% in
placebo + lifestyle
0.1 mmol/L in medication
+ lifestyle vs. 0.2 mmol/L
in placebo + lifestyle
52.8% vs. 37.3% -5.8 Kg in medication
vs.
3 Kg in placebo
w-6.4 cm in
medication +
lifestyle vs. -4.4
cm in placebo+
lifestyle
Absetz, 2009
[77]
3 years
NR 12% of those with IGT
at baseline vs. 1.2% of
those with normal
FPG at baseline
0.0 ± 0.8 mmol/L NR -1 Kg ± 5.6 Kg +0.1 cm ± 6.4 cm
NR = not reported N/A = not applicable.
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Page 9 of 17repporting changes in physical activity, it was not possi-
ble to meta-analyse these outcomes.
Study quality findings
While three of the 12 studies justified their sample sizes
on statistical grounds, and not all adjusted for potential
confounders, the quality of study design and reporting
overall was good in 10 of the 12 studies included, based
on quality criteria scores of 7 or 8 out of 8 (Table 1).
Two studies were considered suboptimal, with quality
scores of 3 or 5 out of 8 respectively [14,84].
Limited generalisability was identified in five studies,
where participants recruited were either self-referred
healthy volunteers [50] or a convenience sample of
males only [49,79], or mostly severely obese middle-age
women [14,78]. Two studies reported higher success
rates for participants who had already met the goals at
baseline [78,82]. In two studies [14,84] the intervention
incurred charges and out-of-pocket expenses for each
session, which lead to differential exposure to intensity
and duration of intervention on the basis of participant’s
ability to pay. Participation rates for the 8 studies
reporting them were satisfactory (median 83.5%). How-
ever, in one of the studies, where the participation rate
was ostensibly 100%, the control group comprised all
those people who did not participate due to financial
reasons (on whom outcome measures were collected,
but possible exposure to other risk reduction regimes
was not recorded) [84].
Loss-to-follow up rates in the 12 studies varied greatly,
from 5% to 57% (median 14%). Differential withdrawal
rates were reported in a further three studies, where a
larger proportion of drop-outs were observed: in partici-
pants at highest baseline risk [78]; in those from the
intensive arm of the intervention [50]; or in subjects
who perceived a poor response to the allocated treat-
ment [80].
Consistency of findings with reference trials
The meta-analysis showed that the pooled weight loss in
the intervention group from the four RCTs yielded a
weight loss of 1.82 Kg at one year (Figure 2), less than
the 5.6 Kg loss observed in the lifestyle-only group of
the reference DPP trial or the 4.2 Kg reported in the
intervention group of the Finnish DPS. While all studies
showed a positive effect on weight loss, only four of the
seven studies, 1 RCT and 3 B-A studies [14,79,80,84]
reported weight changes at 1 year similar in magnitude
to the DPP in the US (around 5 Kg, Table 5). Excepting
the XENical in the Prevention of Diabetes in Obese
Subjects [XENDOS] trial [80], studies reporting propor-
tions achieving a pre-defined weight loss goal of 5% or
7% were less encouraging. Most studies reported half or
less of participants than in the US reference DPP trial,
where 50% of participants achieved 7% weight loss at 6
months [1], or in the Finnish DPS where 43% of partici-
pants achieved 5% weight loss at 1 year.
The one-year improvements in fasting plasma glucose
were similar to the DPP across several studies but were
too small to be clinically important; and reductions of
diabetes incidence in the two studies reporting them at
12 months follow-up [79,83] were somewhat less (37%
and 23% respectively) than the reductions apparent
from the cumulative risk/incidence plots in the Finnish
(~70-80%) and DPP (~70%) trials. For the five studies in
this review measuring waist circumference, all con-
cluded that waist circumference reductions were possi-
ble with modified lifestyle interventions, but after 1 year
only two achieved reductions of sufficient magnitude
that cannot be attributed to measurement error (≥
4 cm) [85]. Decreases in fat consumption and increases
in fibre consumption resulting from interventions gener-
ally were not reported, and the few studies that did
showed no substantial improvements. The exception was
the Absetz et al. trial which reported half the participants
meeting the fibre goal and achieving the total fat intake
goal and a third achieving the saturated fat goal [82].
Feasibility of implementation in routine clinical care
Nine of the 12 studies explored whether translation of
the reference trials into clinical care was feasible. Eight
concluded that modification of the original trial
approaches for adaptation to real life practice made the
lifestyle interventions feasible, affordable or replicable in
clinical care settings despite barriers to implementation
[14,49,78,82-84,86,87]. The remaining study reported
that the transferability of the results from original trials
to other settings remains questionable, as the positive
effect on outcomes diminishes over time [48].
Meta-analysis results
Seven trials which randomised a total of 4,905 partici-
pants to lifestyle intervention or control were identified.
The shortest follow-up period was 4 months and the
longest follow-up period was six years. Four of these,
randomising a total of 1,129 to intervention or control,
reported selected outcomes in comparable units at one
year [48-50,87]. These were meta-analysed, although not
all outcomes of interest were available from all these
studies (Figure 2). We chose not to meta-analyse out-
comes at four [80] or six years [79], as these relate to
the maintenance phase of a program rather than the
medium term impact and it would be inappropriate to
compare them with one-year results.
The systematic review of RCT results at 12-month fol-
low-up showed: mean weight reduction was 1.82 Kg
greater in treatment than control groups which was sta-
tistically significant (95% CI:-2.7 to -0.99 Kg); pooled
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Page 10 of 17mean waist measurement reductions in treatment
exceeded control groups by 4.6 cm, and this was also
significant (95% CI:-5.8 to -3.4 cm); fasting plasma glu-
cose reduction was 0.19 mmol/l greater in treatment
than controls but non-significant (95% CI: -0.44 to
+0.06 mmol/l); and a non-significant greater increase in
2-hour oral glucose tolerance test result of 0.04 mmol/l
(95%CI: -0.49 to +0.42 mmol/l). From the above, it is
apparent that the interventions can achieve significant
weight and waist measurement reductions at one year
but do not significantly change the main metabolic indi-
cators of diabetes risk such as FPG or OGTT.
Four of the 12 studies achieved the greatest weight
l o s s ,i . e .5K go rm o r ea t1 2m o n t h s .A so n l yt w oo f
these successful studies had optimal quality scores
[79,80], we further examined the characteristics of these
studies to identify common determinants of success in
diabetes prevention programs. Common features were
Figure 2 Meta-analyses and pooled estimates of changes in weight, waist measurement, fasting plasma glucose and 2-hour oral
glucose tolerance from selected studies at 1 year follow-up.
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Page 11 of 17RCT design, being based in Sweden, and having long
interventions (1 and 4 years) and longer follow-up peri-
ods (6 years in Malmo, 4 years in XENDOS). They were
not replication studies, and the frequency of participant
contact was amongst the highest, with Malmo providing
12 group sessions and XENDOS providing up to 54
individual counselling sessions. Another common fea-
ture was that following initial substantial weight loss,
Table 5 Comparison of selected effect estimates 1 year after the intervention (among studies meta-analysed and not
meta-analysed)
Author,
year,
reference #
Study
Type
Effect
size for
weight*
%
achieving
a) ≥ 7%
or
b) ≥ 5%
weight
loss
% Reduction
in diabetes
incidence
Effect size
for FPG
mmol/L
Effect size for
2-hr OGTT
mmol/L
Effect for
waist
circumference
(cm)
Effect on fat
intake as % of
total energy
Effect on
fibre intake
g/day
Reference
Trials
DPP
Research
Group, 2002
[1]
RCT -5.6 Kg a) 49% NR
§ -0.3 NR NR -6.6% NR
Finnish DPS
[5]
RCT -4.2 Kg b) 43% NR
§ -0.1 -0.8 -4.4 -21% -12%
Meta-
Analysed
Trials
Barclay, 2008
[87]**
RCT -2.7 Kg NR -0.02 NR -6.01 NR NR
Bo, 2007 [48] RCT -0.75 Kg NR -0.26 NR -2.55 NR +1.7
Kosaka, 2005
[49]
RCT -2.5 Kg 0.5% NR@1 yr NR NR NR NR
Dyson, 1997
[50]
RCT -0.5 Kg NR -0.1 +0.4 NR -3.5% +0.9
Studies Not
Meta-
Analysed
Greaves,
2008 [86]
RCT -0.3 Kg b) 24% NR NR NR -1.6 NR NR
Torgerson,
2004 [80]**
RCT -6.2 Kg NR + 0.2 - 0.4 -7.0 NR NR
Whittemore,
2009 [78]***
ClustRCT -1.5 Kg b) 25% NR NR NR NR NR NR
McTigue,
2009 [84]
BAC - 5.2 Kg a) 27% NR NR NR NR NR NR
Eriksson,
1991 [79]
BAC -5.0 Kg -37% NR -1.5 NR NR NR
Pagoto,
2008 [14]
B-A -5.5 Kg a) 30% NR NR NR NR NR NR
Laatikainen,
2007 [83]
B-A -2.5 Kg -23% - 0.14 - 0.58 -4.2 NR NR
Absetz, 2005
& 2009
[77,82]
B-A -1.0 Kg NR + 0.15 0.0 -1.2 in F
+2.3 in M
NR 52% met
goal
NR = not reported
References to a) or b) indicate comparison to US DPP or Finnish DPS respectively.
* values presented for B-A studies are changes from before to after intervention; values for RCT are differences in change before and after the intervention in the
‘lifestyle treatment’ group only.
§ cumulated diabetes incidence reduction (~58%) reported over 4 and 6 years (US DPP & Finish DPS, respectively).
** values presented as before-after for the lifestyle + placebo group only (excludes effects of medication arm).
*** estimates at 6 months.
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Page 12 of 17the final outcome after several years of follow-up was
only an average of 3 Kg weight loss in both studies. We
may conclude that the outcomes of these two studies
involve social, cultural and health system characteristics
unique to that part of Europe that may not be
generalisable.
Discussion
It is apparent that clinical services are making concerted
efforts to translate lifestyle intervention trials into rou-
tine practice in several countries, whether as pilot stu-
dies or as full-scale interventions. All studies included in
this review recruited individuals at high-risk of diabetes
from IGT, obesity, metabolic syndrome, a combination
of these, or based on other standard inclusion criteria.
All interventions combined dietary and physical activity
and attempted replication of previously published stu-
dies. The wide range of intervention intensities, dura-
tions of follow-up and outcome assessments reflected
the availability of service time, staff skills, levels of reim-
bursement for prevention services, and limited funding
and resources for translation research within the health
systems.
Results from the lifestyle intervention studies that
relied on weight change show promise in achieving
some degree of risk reduction. The weight reduction in
intervention subjects exceeded controls by 1.8 kg, which
was less than that found in the reference U.S. DPP
(5.6 Kg) or the Finnish DPS (4.2 Kg). Results from stu-
dies that relied on changes in fasting plasma glucose or
2-hr plasma glucose as a measure of success, were less
convincing. However, similarly small changes in FPG
after the intervention were also observed in the refer-
ence trials (Table 5). Controlled studies meta-analysed
here were not successful in showing improved glucose
tolerance to a clinically meaningful level that could lead
to diabetes prevention.
The independent effects of physical activity and diet
and other lifestyle changes in the treatment of pre-dia-
betes were not examined in many of the studies
included in this review. Adjustment for covariates/con-
founders generally was not conducted or at least not
reported in those observational studies we examined. It
is possible to combine, ‘meta-analytically’, outcome mea-
sures from observational studies but these must be
adjusted for confounding, preferably the same confound-
ing variables measured similarly across studies. We
excluded from the meta-analysis all observational studies
and some RCT studies due to the heterogeneity of
reported outcome measurements [88].
The results from RCTs of routine clinical practice pre-
sented here would be expected to occur in a real-world
non-experimental setting. However, generalisability from
the observational studies examined here is limited given
the selection bias of some of the intervention and con-
trol groups. The participant population expected
through routine care services is ‘real-life’, self-selected
even if programs are offered to all those eligible free of
charge. The behaviour of people at risk involves refusals,
absenteeism from critical measurement time points and
self-selection of healthier and/or more motivated
patients. In order to achieve results similar to the RCT
evidence, these practical issues of non-compliance
would need particular attention in a real world setting.
The Diabetes in Europe - Prevention using Lifestyle,
Physical Activity and Nutritional intervention (DE-
PLAN) [89] is developing the structures for a prevention
management model which can be implemented in rou-
tine clinical practice settings. Results from this project
should shed further light on specific success factors for
research translation.
This review also examined the feasibility of implemen-
tation of interventions as an integral part of routine
clinical care, as this can inform policy on dissemination
of diabetes prevention programs or associated subsidies
within healthcare systems. To this end, we examined
authors’ conclusions on whether the given intervention
could sustainably be incorporated into usual care pro-
vided, for example, without the need for excessive time
beyond usual consultation, additional funding or con-
tracting of external staff.
Finally, while the outcomes of the two US studies,
where participation incurred a fee, probably are the
most representative of real life in USA, such market-
based rationing of diabetes prevention might not be
acceptable in other health systems, and certainly would
not reach those most in need of such interventions,
including low socio-economic groups and people with
higher prevalence of risk factors for diabetes.
Strengths of this review
T oo u rk n o w l e d g e ,t h i si st h ef i r s ta t t e m p tt oc o m p r e -
hensively compile feasibility and effectiveness of transla-
tion of diabetes prevention trials specifically for routine
clinical settings.
We used a purpose-built comprehensive quality scor-
ing system based on individual components of rele-
vance from checklists widely used by others in quality
assessment of the literature. Our quality criteria
allowed for the inclusion of several study types to
maximise the chances of identifying and assessing rele-
vant diabetes prevention programs. The search was
extensive and individual study authors were contacted
to either confirm that their study was conducted under
r o u t i n ec l i n i c a lc a r eo rt oe x c l u d ea n yt r a n s l a t i o n
study conducted in research settings or under simu-
lated clinical care. Meta-analytic techniques were used
when feasible.
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Despite the good quality of papers covered in this review,
the total number of studies finally included was small;
some were exploratory (3 pilots) and many of them had
short follow-ups and only modest sample sizes which
essentially reflect the financial and time restrictions of
real-life interventions in routine clinical practice. We
included studies with intervention and follow-up durations
of at least 3 months. These are not unusual in routine
practice, as modifications to duration and intensity of the
strict approaches in the reference trials are common in the
replication literature. While longer interventions and fol-
low-up times are ideal, in real-world situations longer stu-
dies inevitably are affected by sample attrition and
attendant generalisability issues. We wanted to include
some measurement of short-term impact and avoid attri-
tion bias and selection bias in our assessment of what is
being evaluated in routine practice and therefore we
allowed for feasibility and pilot studies to be incorporated.
Analyses from before-and-after studies often did not
report on adjustment for confounders. More impor-
tantly, the reporting of outcomes of interest was often
incomplete or in disparate units of measurement pre-
cluding inclusion in the meta-analysis. However, the
overall good quality of these studies enabled their inclu-
sion in the broader systematic review.
Many weight-loss-only programs and other lifestyle
interventions for reduction of cardiovascular disease risk
were excluded as they did not specifically mention repli-
cation of the diabetes prevention trials. However, we
acknowledge that results from these may also be applic-
able to diabetes risk reduction, and while examples of
reviews of these are available in the literature, their
focus is beyond the scope of our review.
Conclusions
Despite convincing evidence from structured intensive
randomised controlled trials in research settings, this
systematic review shows that translation into routine
practice has somewhat less of an impact on diabetes risk
reduction. Given the heterogeneity and limitations of the
studies included in this review, it is also not possible to
d e t e r m i n ec o n c l u s i v e l yw h e t h e rt h et y p eo fc l i n i c a ls e t -
ting, the frequency or intensity of interventions, or the
modality of the intervention (face-to-face, telephone,
written materials, etc) are critical success factors for
translation of diabetes prevention programs in routine
clinical care. Nor was it possible to assess the separate
contributions of individual lifestyle change components
to diabetes risk reduction. Accordingly, we cannot yet
make specific recommendations on the most effective
features of these targeted lifestyle interventions.
However, based on our findings, the direction of the
effects on the four most commonly reported outcomes
(weight, FPG, waist circumference and 2-hour OGTT)
are encouraging; and the consensus on feasibility of
their modification as part of routine care without exces-
sive cost suggest that it is still worth promoting the
translation of modified, group-based lifestyle interven-
tions, and conducting more rigorous evaluations in
these settings. The establishment of a register of transla-
tion projects using consistent, measurable outcomes
would add more certainty to the effectiveness of routine
practice interventions, and when more studies with lar-
ger sample sizes and data on intermediate end-points
become available they could be included in a more com-
prehensive meta-analysis.
Appendix - Description of the search strategy
Electronic sources searched
￿ Articles were identified through searches in MED-
LINE, PubMED, The Cochrane Library, Google Scholar,
CINAHL and EMBASE.
￿ Internet searches and searches of the grey literature
were conducted to identify non peer-reviewed internal
reports from government and health services websites
and non-government sources.
Supplementary sources
￿ Hand searches of reference lists from related articles
found whether or not they were eligible for inclusion in
this review
￿ Hard copy Australian government publications and
unpublished internal reports from key informants for
non-indexed publications.
￿ Authors of reviewed articles were contacted by
MC- M if it was unclear from their papers whether the
intervention was conducted in a research or commu-
nity-based or a routine clinical setting. However, due to
resource constraints, no attempt was made to contact
the investigators whose papers did not report all mea-
sured outcomes.
Search terms
Diabetes, Pre-diabetes, Type 2 diabetes, Impaired glu-
cose tolerance OR glucose intolerance, Lifestyle inter-
vention OR lifestyle program OR strategy, Physical
activity OR Exercise OR Resistance Training, Healthy
eating OR diet OR dietary modification OR weight loss,
Behavioural modification, AND (Primary health care,
General practi$., clinical practice, routine clinical care),
AND (Prevent$. Ti, ab, Translating OR Translation OR
Translat$. Ti, ab., Translation research OR translational
study OR Replication study).
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